Insider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of Stock

ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,810 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $96.03, for a total transaction of $269,844.30. Following the sale, the insider now owns 97,263 shares of the company’s stock, valued at $9,340,165.89. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

David Pendarvis also recently made the following trade(s):

  • On Monday, December 4th, David Pendarvis sold 2,804 shares of ResMed stock. The shares were sold at an average price of $84.17, for a total transaction of $236,012.68.

Shares of ResMed Inc. (NYSE RMD) opened at $89.26 on Friday. The stock has a market cap of $13,233.62, a PE ratio of 29.49 and a beta of 0.92. ResMed Inc. has a 1-year low of $67.04 and a 1-year high of $104.78.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22. The firm had revenue of $601.27 million for the quarter, compared to the consensus estimate of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 EPS. analysts predict that ResMed Inc. will post 3.34 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 8th will be issued a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.57%. The ex-dividend date is Wednesday, February 7th. ResMed’s payout ratio is presently 70.00%.

A number of analysts have weighed in on RMD shares. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research note on Thursday, October 12th. Northland Securities reaffirmed a “sell” rating and set a $55.00 price target on shares of ResMed in a report on Friday, October 27th. BMO Capital Markets raised their price target on shares of ResMed to $82.00 and gave the company a “market perform” rating in a report on Tuesday, December 12th. JPMorgan Chase & Co. raised their price target on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Finally, Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $76.00.

Several hedge funds and other institutional investors have recently made changes to their positions in RMD. Toronto Dominion Bank boosted its holdings in shares of ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 197 shares during the last quarter. Pillar Pacific Capital Management LLC boosted its holdings in shares of ResMed by 1.2% in the fourth quarter. Pillar Pacific Capital Management LLC now owns 43,755 shares of the medical equipment provider’s stock worth $3,706,000 after buying an additional 540 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of ResMed by 3.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,890 shares of the medical equipment provider’s stock worth $1,430,000 after buying an additional 591 shares during the last quarter. WINTON GROUP Ltd boosted its holdings in shares of ResMed by 8.6% in the third quarter. WINTON GROUP Ltd now owns 8,076 shares of the medical equipment provider’s stock worth $622,000 after buying an additional 640 shares during the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of ResMed by 26.7% in the third quarter. Advisor Group Inc. now owns 3,164 shares of the medical equipment provider’s stock worth $244,000 after buying an additional 667 shares during the last quarter. 61.41% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Insider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/09/insider-selling-resmed-inc-rmd-insider-sells-2810-shares-of-stock.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply